期刊
BIOMOLECULES
卷 12, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/biom12081031
关键词
anti-PD-1 antibody; dostarlimab; immunotherapy; clinical trials
资金
- FEDER-Fundo Europeu de Desenvolimento Regional through the COMPETE 2020-Operational Programme for Competitiveness and Internationalization (POCI), Portugal 2020
- FCT-Fundacao para a Ciencia e a Tecnologia [UIDB/4255/2020, RISE-LA/P/0053/2020]
- FCT
- FEDER (European Union) [IF/00092/2014/CP1255/CT0004]
- CHAIR in Onco-Innovation at FMUP
Dostarlimab is a PD-1 monoclonal antibody approved for the treatment of endometrial cancer and has shown promising results in rectal cancer. Ongoing clinical trials are investigating its efficacy in other types of cancer. This article provides a summary of current knowledge on Dostarlimab and explores its potential as a monotherapy or in combination with other treatments.
Dostarlimab (JEMPERLI) is a PD-1 monoclonal antibody for the treatment of adult patients, with mismatch repair deficient (dMMR), recurrent or advanced endometrial cancer that has progressed on or following prior therapy with a platinum-containing regimen. As determined by an FDA-approved test this indication was granted rapid approval based on the rate of tumor response and the duration of the response. Continued approval for this indication is conditioned on further confirmatory trials demonstrating and documenting clinical benefit. In June 2022, the clinical trial NCT04165772 reported a 100% remission rate for rectal cancer. This clinical trial brought proof that we can match a tumor and the genetics of what is driving it, with therapy. This clinical trial continues to enroll patient and is currently enrolling patients with gastric, prostate, and pancreatic cancers. Dostarlamib is being recommended for rectal cancer. The focus of this review is to summarize the existing knowledge regarding Dostarlimab and explore the possibilities of mono- and combination therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据